報價延遲最少15分鐘:2026/04/25 05:35 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
1.05 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-1.35/-0.41
|
|
企業價值
44.12M
|
| 資產負債 |
|
每股賬面淨值
0.25
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Mira Pharmaceuticals Inc is a clinical-stage pharmaceutical development company focused on developing novel oral small-molecule therapeutics for neurologic, neuropsychiatric, metabolic, and inflammatory disorders. The company's pipeline includes three product candidates: Ketamir-2, MIRA-55, and SKNY-1, three drug candidates designed to address unmet medical needs across neuropathic and inflammatory pain, central nervous system disorders, and metabolic and behavioral conditions. The company operates as a single operating and reportable segment. |
